Source:http://linkedlifedata.com/resource/pubmed/id/11724218
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
11 Pt 1
|
| pubmed:dateCreated |
2001-11-28
|
| pubmed:commentsCorrections | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Nov
|
| pubmed:issn |
0895-7061
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
14
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1170-2
|
| pubmed:dateRevised |
2009-2-24
|
| pubmed:meshHeading |
pubmed-meshheading:11724218-Adrenergic alpha-Antagonists,
pubmed-meshheading:11724218-Antihypertensive Agents,
pubmed-meshheading:11724218-Clinical Trials as Topic,
pubmed-meshheading:11724218-Doxazosin,
pubmed-meshheading:11724218-Humans,
pubmed-meshheading:11724218-Hypertension,
pubmed-meshheading:11724218-Treatment Outcome
|
| pubmed:year |
2001
|
| pubmed:articleTitle |
Doxazosin for the management of hypertension: implications of the findings of the ALLHAT trial.
|
| pubmed:publicationType |
Letter
|